PAM
AEGR

Paradigm Asset Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Paradigm Asset Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,500
Closed -$47.6K – 894
2015
Q3 		$47.6K Sell
3,500
-650
-16% -$11.6K 0.01% 645
2015
Q2 		$78.7K Hold
4,150
– – 0.01% 587
2015
Q1 		$109K Hold
4,150
– – 0.01% 537
2014
Q4 		$86.9K Hold
4,150
– – 0.01% 569
2014
Q3 		$139K Sell
4,150
-4,150
-50% -$129K 0.02% 503
2014
Q2 		$266K Buy
8,300
+1,800
+28% +$67K 0.04% 457
2014
Q1 		$300K Hold
6,500
– – 0.04% 427
2013
Q4 		$461K Hold
6,500
– – 0.07% 330
2013
Q3 		$557K Buy
+6,500
New +$551K 0.09% 242

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Paradigm Asset Management's AEGR Position: Q4 2015 in Review

Paradigm Asset Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 3,500 shares — an estimated $47.6K sold.

Paradigm Asset Management first reported a position in AEGR in Q3 2013 and held it in 9 quarters. The position peaked at $557K in Q3 2013. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • Paradigm Asset Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Paradigm Asset Management sold 3,500 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $47.6K.
  • Paradigm Asset Management first reported a position in Aegerion Pharmaceuticals in Q3 2013 and held it in 9 quarters.
  • Paradigm Asset Management's Aegerion Pharmaceuticals position peaked at $557K in Q3 2013.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on Paradigm Asset Management's 13F filing for Q4 2015, filed 5 Feb 2016.